Comparison of morphine concentration-time profiles following intravenous and intranasal diamorphine in children
- PMID: 19793724
- DOI: 10.1136/adc.2008.140194
Comparison of morphine concentration-time profiles following intravenous and intranasal diamorphine in children
Abstract
Background: Current best practice for treating acute severe pain in children is to administer intravenous or intranasal opioid. Intranasal diamorphine offers less traumatic analgesia than the potentially difficult and distressing intravenous route. However, there has been no direct comparison of intranasal and intravenous diamorphine nor are there pharmacokinetic data for intranasal diamorphine in children.
Objective: To compare plasma morphine concentration-time profiles following intranasal and intravenous diamorphine administration.
Design: Observational.
Setting: A&E department in a city-centre paediatric teaching hospital.
Patients: Children, aged 3-13 years, with isolated limb fracture.
Interventions: An intravenous catheter was sited and baseline blood taken. The first 12 children received intravenous diamorphine (0.1 mg/kg), and the subsequent 12 intranasal diamorphine (0.1 mg/kg) in 0.2 ml sterile water drops. Subsequent samples were taken at 2, 5, 10, 20, 30 and 60 min.
Measurements: Plasma morphine radioimmunoassay.
Results: Peak plasma morphine concentrations were higher (median 109 vs 36 nmol/l), and occurred earlier (median 2 vs 10 min), with greater area under the curve (3761 vs 1794 nmol/l/h) following intravenous compared to intranasal diamorphine (all p<0.001, Mann-Whitney U test). Higher plasma concentrations at 60 min (47 vs 32 nmol/l) were also observed following intravenous diamorphine (p = 0.01, Mann-Whitney U test).
Conclusions: Our evidence supports the wider use of diamorphine administration by nasal drops in children, as it shows that adequate plasma levels of morphine are usually achieved. However, we demonstrated significantly attenuated and delayed peak plasma morphine levels with lower levels at 1 h with intranasal compared with intravenous diamorphine.
Similar articles
-
Nose and vein, speed and pain: comparing the use of intranasal diamorphine and intravenous morphine in a Scottish paediatric emergency department.Emerg Med J. 2013 Jan;30(1):49-52. doi: 10.1136/emermed-2011-200970. Epub 2012 Mar 12. Emerg Med J. 2013. PMID: 22411597
-
Intranasal diamorphine for acute sickle cell pain.Arch Dis Child. 2009 Dec;94(12):979-80. doi: 10.1136/adc.2008.138875. Epub 2009 Mar 25. Arch Dis Child. 2009. PMID: 19321506 Clinical Trial.
-
Intranasal diamorphine as an alternative to intramuscular morphine: pharmacokinetic and pharmacodynamic aspects.Clin Pharmacokinet. 2003;42(6):501-13. doi: 10.2165/00003088-200342060-00001. Clin Pharmacokinet. 2003. PMID: 12793836
-
Diamorphine pharmacokinetics and conversion factor estimates for intranasal diamorphine in paediatric breakthrough pain:systematic review.BMJ Support Palliat Care. 2024 Jan 8;13(e3):e485-e493. doi: 10.1136/bmjspcare-2021-003461. BMJ Support Palliat Care. 2024. PMID: 35184039
-
Pharmacokinetic modeling and simulation to understand diamorphine dose-response in neonates, children, and adolescents.Paediatr Anaesth. 2022 Jun;32(6):716-726. doi: 10.1111/pan.14425. Epub 2022 Mar 1. Paediatr Anaesth. 2022. PMID: 35212432 Review.
Cited by
-
Intranasal diamorphine population pharmacokinetics modeling and simulation in pediatric breakthrough pain.CPT Pharmacometrics Syst Pharmacol. 2025 Mar;14(3):435-447. doi: 10.1002/psp4.13186. Epub 2025 Feb 13. CPT Pharmacometrics Syst Pharmacol. 2025. PMID: 39949065 Free PMC article.
-
Pain Management of Pediatric Musculoskeletal Injury in the Emergency Department: A Systematic Review.Pain Res Manag. 2016;2016:4809394. doi: 10.1155/2016/4809394. Epub 2016 Apr 11. Pain Res Manag. 2016. PMID: 27445614 Free PMC article.
-
Managing Pediatric Pain in the Emergency Department.Paediatr Drugs. 2016 Aug;18(4):287-301. doi: 10.1007/s40272-016-0181-5. Paediatr Drugs. 2016. PMID: 27260499 Review.
-
Buprenorphine Increases HIV-1 Infection In Vitro but Does Not Reactivate HIV-1 from Latency.Viruses. 2021 Jul 27;13(8):1472. doi: 10.3390/v13081472. Viruses. 2021. PMID: 34452338 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources